SciBase Secures SEK 57.5M as Rights Issue Fully Subscribed
Stockholm – October 01, 2026 -- SciBase Holding AB has closed its rights issue fully subscribed, raising approximately SEK 57.5 million before issue costs to fund continued commercialisation of its Nevisense melanoma-diagnostics platform in the United States.
Shareholders cover nearly three-quarters of the offering
The subscription period, which ran through 29 September 2026, saw 2,681,085 shares subscribed with the support of subscription rights, equal to roughly SEK 40.2 million, or 69.9 percent of the issue. An additional 133,116 shares were subscribed without subscription rights, adding SEK 2.0 million, or 3.5 percent. In total, 2,814,201 shares were subscribed with and without rights, covering approximately SEK 42.2 million, or 73.4 percent of the SEK 57.5 million target.